

# DYNAVAX

## Dynavax to Present at the 3rd Annual Evercore Virtual ISI HealthCONx Conference

November 17, 2020

EMERYVILLE, Calif., Nov. 17, 2020 /PRNewswire/ -- [Dynavax Technologies Corporation](#) (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that [Ryan Spencer](#), Chief Executive Officer, will participate in a virtual fireside chat at the 3rd Annual Evercore virtual ISI HealthCONx Conference on Thursday, December 3, at 10:05 a. m. E.T.



The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at [www.dynavax.com](http://www.dynavax.com). A replay of the webcast will be available for 30 days following the live event.

### About Dynavax

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit [www.dynavax.com](http://www.dynavax.com) and follow the company on [LinkedIn](#).

### Contacts:

Nicole Arndt, Senior Manager, Investor Relations  
[narndt@dynavax.com](mailto:narndt@dynavax.com)  
510-665-7264

Derek Cole, President  
Investor Relations Advisory Solutions  
[derek.cole@IRadvisory.com](mailto:derek.cole@IRadvisory.com)

 View original content to download multimedia: <http://www.prnewswire.com/news-releases/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference-301175311.html>

SOURCE Dynavax Technologies